Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 231 entries
Sorted by: Best Match Show Resources per page
Cystic fibrosis.

American journal of respiratory and critical care medicine

Davis PB, Drumm M, Konstan MW.
PMID: 8912731
Am J Respir Crit Care Med. 1996 Nov;154(5):1229-56. doi: 10.1164/ajrccm.154.5.8912731.

No abstract available.

Cite
Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med. 1996;154(5):1229-56doi: 10.1164/ajrccm.154.5.8912731.
Davis, P. B., Drumm, M., & Konstan, M. W. (1996). Cystic fibrosis. American journal of respiratory and critical care medicine, 154(5), 1229-56. https://doi.org/10.1164/ajrccm.154.5.8912731
Davis, P B, et al. "Cystic fibrosis." American journal of respiratory and critical care medicine vol. 154,5 (1996): 1229-56. doi: https://doi.org/10.1164/ajrccm.154.5.8912731
Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med. 1996 Nov;154(5):1229-56. doi: 10.1164/ajrccm.154.5.8912731. PMID: 8912731.
Copy Download .nbib Format: NLM
Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations : An overview and recommendations of the consortium academic radiation oncology of the German Society for Radiation Oncology (DEGRO).

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Dapper H, Belka C, Bock F, Budach V, Budach W, Christiansen H, Debus J, Distel L, Dunst J, Eckert F, Eich H, Eicheler W, Engenhart-Cabillic R, Fietkau R, Fleischmann DF, Frerker B, Giordano FA, Grosu AL, Herfarth K, Hildebrandt G, Kaul D, Kölbl O, Krause M, Krug D, Martin D, Matuschek C, Medenwald D, Nicolay NH, Niewald M, Oertel M, Petersen C, Pohl F, Raabe A, Rödel C, Rübe C, Schmalz C, Schmeel LC, Steinmann D, Stüben G, Thamm R, Vordermark D, Vorwerk H, Wiegel T, Zips D, Combs SE.
PMID: 34786605
Strahlenther Onkol. 2022 Jan;198(1):1-11. doi: 10.1007/s00066-021-01861-7. Epub 2021 Nov 16.

The new Medical Licensing Regulations 2025 (Ärztliche Approbationsordnung, ÄApprO) will soon be passed by the Federal Council (Bundesrat) and will be implemented step by step by the individual faculties in the coming months. The further development of medical studies...

Cite
Dapper H, Belka C, Bock F, et al. Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations : An overview and recommendations of the consortium academic radiation oncology of the German Society for Radiation Oncology (DEGRO). Strahlenther Onkol. 2021;198(1):1-11doi: 10.1007/s00066-021-01861-7.
Dapper, H., Belka, C., Bock, F., Budach, V., Budach, W., Christiansen, H., Debus, J., Distel, L., Dunst, J., Eckert, F., Eich, H., Eicheler, W., Engenhart-Cabillic, R., Fietkau, R., Fleischmann, D. F., Frerker, B., Giordano, F. A., Grosu, A. L., Herfarth, K., Hildebrandt, G., Kaul, D., Kölbl, O., Krause, M., Krug, D., Martin, D., Matuschek, C., Medenwald, D., Nicolay, N. H., Niewald, M., Oertel, M., Petersen, C., Pohl, F., Raabe, A., Rödel, C., Rübe, C., Schmalz, C., Schmeel, L. C., Steinmann, D., Stüben, G., Thamm, R., Vordermark, D., Vorwerk, H., Wiegel, T., Zips, D., & Combs, S. E. (2022). Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations : An overview and recommendations of the consortium academic radiation oncology of the German Society for Radiation Oncology (DEGRO). Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 198(1), 1-11. https://doi.org/10.1007/s00066-021-01861-7
Dapper, H, et al. "Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations : An overview and recommendations of the consortium academic radiation oncology of the German Society for Radiation Oncology (DEGRO)." Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] vol. 198,1 (2022): 1-11. doi: https://doi.org/10.1007/s00066-021-01861-7
Dapper H, Belka C, Bock F, Budach V, Budach W, Christiansen H, Debus J, Distel L, Dunst J, Eckert F, Eich H, Eicheler W, Engenhart-Cabillic R, Fietkau R, Fleischmann DF, Frerker B, Giordano FA, Grosu AL, Herfarth K, Hildebrandt G, Kaul D, Kölbl O, Krause M, Krug D, Martin D, Matuschek C, Medenwald D, Nicolay NH, Niewald M, Oertel M, Petersen C, Pohl F, Raabe A, Rödel C, Rübe C, Schmalz C, Schmeel LC, Steinmann D, Stüben G, Thamm R, Vordermark D, Vorwerk H, Wiegel T, Zips D, Combs SE. Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations : An overview and recommendations of the consortium academic radiation oncology of the German Society for Radiation Oncology (DEGRO). Strahlenther Onkol. 2022 Jan;198(1):1-11. doi: 10.1007/s00066-021-01861-7. Epub 2021 Nov 16. PMID: 34786605; PMCID: PMC8594460.
Copy Download .nbib Format: NLM
Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy.

eNeurologicalSci

Bolz S, Ramakrishnan T, Fleischer M, Livingstone E, Stolte B, Thimm A, Kizina K, Ugurel S, Kleinschnitz C, Glas M, Zimmer L, Hagenacker T.
PMID: 33604462
eNeurologicalSci. 2021 Feb 01;22:100324. doi: 10.1016/j.ensci.2021.100324. eCollection 2021 Mar.

BACKGROUND: Checkpoint inhibitors show impressive and durable responses in various cancer types and provide new avenues for cancer immunotherapy. However, these drugs have a variety of adverse events. Common autoimmune-related adverse effects include fatigue, hepatitis, skin rash, endocrine deficiencies,...

Cite
Bolz S, Ramakrishnan T, Fleischer M, et al. Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy. eNeurologicalSci. 2021;22:100324doi: 10.1016/j.ensci.2021.100324.
Bolz, S., Ramakrishnan, T., Fleischer, M., Livingstone, E., Stolte, B., Thimm, A., Kizina, K., Ugurel, S., Kleinschnitz, C., Glas, M., Zimmer, L., & Hagenacker, T. (2021). Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy. eNeurologicalSci, 22100324. https://doi.org/10.1016/j.ensci.2021.100324
Bolz, Saskia, et al. "Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy." eNeurologicalSci vol. 22 (2021): 100324. doi: https://doi.org/10.1016/j.ensci.2021.100324
Bolz S, Ramakrishnan T, Fleischer M, Livingstone E, Stolte B, Thimm A, Kizina K, Ugurel S, Kleinschnitz C, Glas M, Zimmer L, Hagenacker T. Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy. eNeurologicalSci. 2021 Feb 01;22:100324. doi: 10.1016/j.ensci.2021.100324. eCollection 2021 Mar. PMID: 33604462; PMCID: PMC7876540.
Copy Download .nbib Format: NLM
Comparison of unenhanced magnetic resonance imaging and ultrasound in detecting very small hepatocellular carcinoma.

World journal of hepatology

Tarao K, Nozaki A, Komatsu H, Komatsu T, Taguri M, Tanaka K, Yoshida T, Koyasu H, Chuma M, Numata K, Maeda S.
PMID: 34239704
World J Hepatol. 2021 Jun 27;13(6):699-708. doi: 10.4254/wjh.v13.i6.699.

BACKGROUND: In hepatocellular carcinoma (HCC), detection and treatment prior to growth beyond 2 cm are important as a larger tumor size is more frequently associated with microvascular invasion and/or satellites. In the surveillance of very small HCC nodules (≤...

Cite
Tarao K, Nozaki A, Komatsu H, et al. Comparison of unenhanced magnetic resonance imaging and ultrasound in detecting very small hepatocellular carcinoma. World J Hepatol. 2021;13(6):699-708doi: 10.4254/wjh.v13.i6.699.
Tarao, K., Nozaki, A., Komatsu, H., Komatsu, T., Taguri, M., Tanaka, K., Yoshida, T., Koyasu, H., Chuma, M., Numata, K., & Maeda, S. (2021). Comparison of unenhanced magnetic resonance imaging and ultrasound in detecting very small hepatocellular carcinoma. World journal of hepatology, 13(6), 699-708. https://doi.org/10.4254/wjh.v13.i6.699
Tarao, Kazuo, et al. "Comparison of unenhanced magnetic resonance imaging and ultrasound in detecting very small hepatocellular carcinoma." World journal of hepatology vol. 13,6 (2021): 699-708. doi: https://doi.org/10.4254/wjh.v13.i6.699
Tarao K, Nozaki A, Komatsu H, Komatsu T, Taguri M, Tanaka K, Yoshida T, Koyasu H, Chuma M, Numata K, Maeda S. Comparison of unenhanced magnetic resonance imaging and ultrasound in detecting very small hepatocellular carcinoma. World J Hepatol. 2021 Jun 27;13(6):699-708. doi: 10.4254/wjh.v13.i6.699. PMID: 34239704; PMCID: PMC8239491.
Copy Download .nbib Format: NLM
Candidates for area under the concentration-time curve (AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients.

Journal of global antimicrobial resistance

Hashimoto N, Kimura T, Hamada Y, Niwa T, Hanai Y, Chuma M, Fujii S, Matsumoto K, Shigemi A, Kawamura H, Takahashi Y, Takesue Y.
PMID: 34371241
J Glob Antimicrob Resist. 2021 Dec;27:12-19. doi: 10.1016/j.jgar.2021.07.018. Epub 2021 Aug 08.

OBJECTIVES: Compared with vancomycin trough concentration (CMETHODS: A multivariate logistic regression analysis was applied to identify risk factors for AKI. Additionally, the cut‑off day for AKI onset, cut-off CRESULTS: In total, 8.4% (159/1882) of patients developed AKI. AKI occurred...

Cite
Hashimoto N, Kimura T, Hamada Y, et al. Candidates for area under the concentration-time curve (AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients. J Glob Antimicrob Resist. 2021;27:12-19doi: 10.1016/j.jgar.2021.07.018.
Hashimoto, N., Kimura, T., Hamada, Y., Niwa, T., Hanai, Y., Chuma, M., Fujii, S., Matsumoto, K., Shigemi, A., Kawamura, H., Takahashi, Y., & Takesue, Y. (2021). Candidates for area under the concentration-time curve (AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients. Journal of global antimicrobial resistance, 2712-19. https://doi.org/10.1016/j.jgar.2021.07.018
Hashimoto, Naoto, et al. "Candidates for area under the concentration-time curve (AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients." Journal of global antimicrobial resistance vol. 27 (2021): 12-19. doi: https://doi.org/10.1016/j.jgar.2021.07.018
Hashimoto N, Kimura T, Hamada Y, Niwa T, Hanai Y, Chuma M, Fujii S, Matsumoto K, Shigemi A, Kawamura H, Takahashi Y, Takesue Y. Candidates for area under the concentration-time curve (AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients. J Glob Antimicrob Resist. 2021 Dec;27:12-19. doi: 10.1016/j.jgar.2021.07.018. Epub 2021 Aug 08. PMID: 34371241.
Copy Download .nbib Format: NLM
Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease.

Stem cells and development

Döring M, Cabanillas Stanchi KM, Lenglinger K, Treuner C, Gieseke F, Erbacher A, Mezger M, Vaegler M, Schlegel PG, Greil J, Bettoni da Cunha Riehm C, Faul C, Schumm M, Lang P, Handgretinger R, Müller I.
PMID: 33446053
Stem Cells Dev. 2021 Mar;30(5):234-246. doi: 10.1089/scd.2020.0191. Epub 2021 Feb 19.

Steroid-refractory graft-versus-host disease (GvHD) is a life-threatening complication after allogeneic hematopoietic stem cell transplantation (alloHSCT). Alternative treatment options are often insufficient. Several studies have proven the efficacy of mesenchymal stromal cells (MSCs) in the treatment of therapy-refractory acute GvHD...

Cite
Döring M, Cabanillas Stanchi KM, Lenglinger K, et al. Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease. Stem Cells Dev. 2021;30(5):234-246doi: 10.1089/scd.2020.0191.
Döring, M., Cabanillas Stanchi, K. M., Lenglinger, K., Treuner, C., Gieseke, F., Erbacher, A., Mezger, M., Vaegler, M., Schlegel, P. G., Greil, J., Bettoni da Cunha Riehm, C., Faul, C., Schumm, M., Lang, P., Handgretinger, R., & Müller, I. (2021). Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease. Stem cells and development, 30(5), 234-246. https://doi.org/10.1089/scd.2020.0191
Döring, Michaela, et al. "Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease." Stem cells and development vol. 30,5 (2021): 234-246. doi: https://doi.org/10.1089/scd.2020.0191
Döring M, Cabanillas Stanchi KM, Lenglinger K, Treuner C, Gieseke F, Erbacher A, Mezger M, Vaegler M, Schlegel PG, Greil J, Bettoni da Cunha Riehm C, Faul C, Schumm M, Lang P, Handgretinger R, Müller I. Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease. Stem Cells Dev. 2021 Mar;30(5):234-246. doi: 10.1089/scd.2020.0191. Epub 2021 Feb 19. PMID: 33446053.
Copy Download .nbib Format: NLM
Assessment of Bulbar Function in Adult Patients with 5q-SMA Type 2 and 3 under Treatment with Nusinersen.

Brain sciences

Brakemeier S, Stolte B, Thimm A, Kizina K, Totzeck A, Munoz-Rosales J, Kleinschnitz C, Hagenacker T.
PMID: 34573264
Brain Sci. 2021 Sep 20;11(9). doi: 10.3390/brainsci11091244.

The antisense oligonucleotide nusinersen has been shown to improve trunk and limb motor function in patients with spinal muscular atrophy (SMA). Bulbar dysfunction, which is regularly present in SMA, is not captured by standard motor scores, and validated measurement...

Cite
Brakemeier S, Stolte B, Thimm A, et al. Assessment of Bulbar Function in Adult Patients with 5q-SMA Type 2 and 3 under Treatment with Nusinersen. Brain Sci. 2021;11(9)doi: 10.3390/brainsci11091244.
Brakemeier, S., Stolte, B., Thimm, A., Kizina, K., Totzeck, A., Munoz-Rosales, J., Kleinschnitz, C., & Hagenacker, T. (2021). Assessment of Bulbar Function in Adult Patients with 5q-SMA Type 2 and 3 under Treatment with Nusinersen. Brain sciences, 11(9), . https://doi.org/10.3390/brainsci11091244
Brakemeier, Svenja, et al. "Assessment of Bulbar Function in Adult Patients with 5q-SMA Type 2 and 3 under Treatment with Nusinersen." Brain sciences vol. 11,9 (2021). doi: https://doi.org/10.3390/brainsci11091244
Brakemeier S, Stolte B, Thimm A, Kizina K, Totzeck A, Munoz-Rosales J, Kleinschnitz C, Hagenacker T. Assessment of Bulbar Function in Adult Patients with 5q-SMA Type 2 and 3 under Treatment with Nusinersen. Brain Sci. 2021 Sep 20;11(9). doi: 10.3390/brainsci11091244. PMID: 34573264; PMCID: PMC8470195.
Copy Download .nbib Format: NLM
Academic investigators' interest in promoting specified clinical trials : Questionnaire survey before and after implementation of the Clinical Trial Act.

The journal of medical investigation : JMI

Chuma M, Takechi K, Yagi K, Sakaguchi S, Nokihara H, Kane C, Sato Y, Niimura T, Goda M, Zamami Y, Ishizawa K, Yanagawa H.
PMID: 33994483
J Med Invest. 2021;68(1):71-75. doi: 10.2152/jmi.68.71.

Background : Enforcement of the 2018 Clinical Trials Act (CTA) in Japan resulted in strict and complicated regulations surrounding intervention studies. Few Japan-specific measures have been developed to promote intervention studies in Japan despite concerns about CTA's negative influence...

Cite
Chuma M, Takechi K, Yagi K, et al. Academic investigators' interest in promoting specified clinical trials : Questionnaire survey before and after implementation of the Clinical Trial Act. J Med Invest. 2021;68(1):71-75doi: 10.2152/jmi.68.71.
Chuma, M., Takechi, K., Yagi, K., Sakaguchi, S., Nokihara, H., Kane, C., Sato, Y., Niimura, T., Goda, M., Zamami, Y., Ishizawa, K., & Yanagawa, H. (2021). Academic investigators' interest in promoting specified clinical trials : Questionnaire survey before and after implementation of the Clinical Trial Act. The journal of medical investigation : JMI, 68(1), 71-75. https://doi.org/10.2152/jmi.68.71
Chuma, Masayuki, et al. "Academic investigators' interest in promoting specified clinical trials : Questionnaire survey before and after implementation of the Clinical Trial Act." The journal of medical investigation : JMI vol. 68,1 (2021): 71-75. doi: https://doi.org/10.2152/jmi.68.71
Chuma M, Takechi K, Yagi K, Sakaguchi S, Nokihara H, Kane C, Sato Y, Niimura T, Goda M, Zamami Y, Ishizawa K, Yanagawa H. Academic investigators' interest in promoting specified clinical trials : Questionnaire survey before and after implementation of the Clinical Trial Act. J Med Invest. 2021;68(1):71-75. doi: 10.2152/jmi.68.71. PMID: 33994483.
Copy Download .nbib Format: NLM
Sequential therapy from entecavir to tenofovir alafenamide .

JGH open : an open access journal of gastroenterology and hepatology

Itokawa N, Atsukawa M, Tsubota A, Takaguchi K, Nakamuta M, Hiraoka A, Kato K, Abe H, Mikami S, Shimada N, Chuma M, Akito N, Uojima H, Ogawa C, Asano T, Tani J, Morishita A, Senoh T, Yamashita N, Oikawa T, Matsumoto Y, Koeda M, Yoshida Y, Tanabe T, Okubo T, Arai T, Hayama K, Iwashita AN, Kondo C, Tada T, Toyoda H, Kumada T, Iwakiri K.
PMID: 33490611
JGH Open. 2020 Nov 02;5(1):34-40. doi: 10.1002/jgh3.12443. eCollection 2021 Jan.

BACKGROUND AND AIM: Although tenofovir alafenamide (TAF), as well as entecavir (ETV), is widely used as first-line treatment for patients with chronic hepatitis B, there are only a few studies comparing sequential therapy from ETV to TAF and continuous...

Cite
Itokawa N, Atsukawa M, Tsubota A, et al. Sequential therapy from entecavir to tenofovir alafenamide . JGH Open. 2020;5(1):34-40doi: 10.1002/jgh3.12443.
Itokawa, N., Atsukawa, M., Tsubota, A., Takaguchi, K., Nakamuta, M., Hiraoka, A., Kato, K., Abe, H., Mikami, S., Shimada, N., Chuma, M., Akito, N., Uojima, H., Ogawa, C., Asano, T., Tani, J., Morishita, A., Senoh, T., Yamashita, N., Oikawa, T., Matsumoto, Y., Koeda, M., Yoshida, Y., Tanabe, T., Okubo, T., Arai, T., Hayama, K., Iwashita, A. N., Kondo, C., Tada, T., Toyoda, H., Kumada, T., & Iwakiri, K. (2021). Sequential therapy from entecavir to tenofovir alafenamide . JGH open : an open access journal of gastroenterology and hepatology, 5(1), 34-40. https://doi.org/10.1002/jgh3.12443
Itokawa, Norio, et al. "Sequential therapy from entecavir to tenofovir alafenamide ." JGH open : an open access journal of gastroenterology and hepatology vol. 5,1 (2021): 34-40. doi: https://doi.org/10.1002/jgh3.12443
Itokawa N, Atsukawa M, Tsubota A, Takaguchi K, Nakamuta M, Hiraoka A, Kato K, Abe H, Mikami S, Shimada N, Chuma M, Akito N, Uojima H, Ogawa C, Asano T, Tani J, Morishita A, Senoh T, Yamashita N, Oikawa T, Matsumoto Y, Koeda M, Yoshida Y, Tanabe T, Okubo T, Arai T, Hayama K, Iwashita AN, Kondo C, Tada T, Toyoda H, Kumada T, Iwakiri K. Sequential therapy from entecavir to tenofovir alafenamide . JGH Open. 2020 Nov 02;5(1):34-40. doi: 10.1002/jgh3.12443. eCollection 2021 Jan. PMID: 33490611; PMCID: PMC7812481.
Copy Download .nbib Format: NLM
Search for Therapeutic Agents for Cardiac Arrest Using a Drug Discovery Tool and Large-Scale Medical Information Database.

Frontiers in pharmacology

Zamami Y, Niimura T, Koyama T, Shigemi Y, Izawa-Ishizawa Y, Morita M, Ohshima A, Harada K, Imai T, Hagiwara H, Okada N, Goda M, Takechi K, Chuma M, Kondo Y, Tsuchiya K, Hinotsu S, Kano MR, Ishizawa K.
PMID: 31780928
Front Pharmacol. 2019 Nov 08;10:1257. doi: 10.3389/fphar.2019.01257. eCollection 2019.

The survival rate of cardiac arrest patients is less than 10%; therefore, development of a therapeutic strategy that improves their prognosis is necessary. Herein, we searched data collected from medical facilities throughout Japan for drugs that improve the survival...

Cite
Zamami Y, Niimura T, Koyama T, et al. Search for Therapeutic Agents for Cardiac Arrest Using a Drug Discovery Tool and Large-Scale Medical Information Database. Front Pharmacol. 2019;10:1257doi: 10.3389/fphar.2019.01257.
Zamami, Y., Niimura, T., Koyama, T., Shigemi, Y., Izawa-Ishizawa, Y., Morita, M., Ohshima, A., Harada, K., Imai, T., Hagiwara, H., Okada, N., Goda, M., Takechi, K., Chuma, M., Kondo, Y., Tsuchiya, K., Hinotsu, S., Kano, M. R., & Ishizawa, K. (2019). Search for Therapeutic Agents for Cardiac Arrest Using a Drug Discovery Tool and Large-Scale Medical Information Database. Frontiers in pharmacology, 101257. https://doi.org/10.3389/fphar.2019.01257
Zamami, Yoshito, et al. "Search for Therapeutic Agents for Cardiac Arrest Using a Drug Discovery Tool and Large-Scale Medical Information Database." Frontiers in pharmacology vol. 10 (2019): 1257. doi: https://doi.org/10.3389/fphar.2019.01257
Zamami Y, Niimura T, Koyama T, Shigemi Y, Izawa-Ishizawa Y, Morita M, Ohshima A, Harada K, Imai T, Hagiwara H, Okada N, Goda M, Takechi K, Chuma M, Kondo Y, Tsuchiya K, Hinotsu S, Kano MR, Ishizawa K. Search for Therapeutic Agents for Cardiac Arrest Using a Drug Discovery Tool and Large-Scale Medical Information Database. Front Pharmacol. 2019 Nov 08;10:1257. doi: 10.3389/fphar.2019.01257. eCollection 2019. PMID: 31780928; PMCID: PMC6857070.
Copy Download .nbib Format: NLM
Impact of Area Under the Concentration-Time Curve on the Prevalence of Vancomycin-Induced Nephrotoxicity in Combination With Tazobactam/Piperacillin or Cefepime: A Single-Institution Retrospective Study.

Clinical therapeutics

Okada N, Izumi Y, Nakamoto A, Chuma M, Goda M, Yagi K, Aizawa F, Hamano H, Zamami Y, Azuma M, Ishizawa K.
PMID: 34642081
Clin Ther. 2021 Nov;43(11):1910-1920.e3. doi: 10.1016/j.clinthera.2021.09.007. Epub 2021 Oct 09.

PURPOSE: Risk for vancomycin-induced nephrotoxicity (VIN) is reportedly reduced by AUC-guided vancomycin dosing. However, it remains unknown whether the increased VIN risk in combination treatment with vancomycin and tazobactam/piperacillin, which is a VIN risk factor, can be diminished by...

Cite
Okada N, Izumi Y, Nakamoto A, et al. Impact of Area Under the Concentration-Time Curve on the Prevalence of Vancomycin-Induced Nephrotoxicity in Combination With Tazobactam/Piperacillin or Cefepime: A Single-Institution Retrospective Study. Clin Ther. 2021;43(11):1910-1920.e3doi: 10.1016/j.clinthera.2021.09.007.
Okada, N., Izumi, Y., Nakamoto, A., Chuma, M., Goda, M., Yagi, K., Aizawa, F., Hamano, H., Zamami, Y., Azuma, M., & Ishizawa, K. (2021). Impact of Area Under the Concentration-Time Curve on the Prevalence of Vancomycin-Induced Nephrotoxicity in Combination With Tazobactam/Piperacillin or Cefepime: A Single-Institution Retrospective Study. Clinical therapeutics, 43(11), 1910-1920.e3. https://doi.org/10.1016/j.clinthera.2021.09.007
Okada, Naoto, et al. "Impact of Area Under the Concentration-Time Curve on the Prevalence of Vancomycin-Induced Nephrotoxicity in Combination With Tazobactam/Piperacillin or Cefepime: A Single-Institution Retrospective Study." Clinical therapeutics vol. 43,11 (2021): 1910-1920.e3. doi: https://doi.org/10.1016/j.clinthera.2021.09.007
Okada N, Izumi Y, Nakamoto A, Chuma M, Goda M, Yagi K, Aizawa F, Hamano H, Zamami Y, Azuma M, Ishizawa K. Impact of Area Under the Concentration-Time Curve on the Prevalence of Vancomycin-Induced Nephrotoxicity in Combination With Tazobactam/Piperacillin or Cefepime: A Single-Institution Retrospective Study. Clin Ther. 2021 Nov;43(11):1910-1920.e3. doi: 10.1016/j.clinthera.2021.09.007. Epub 2021 Oct 09. PMID: 34642081.
Copy Download .nbib Format: NLM
Impact of Area Under the Concentration-Time Curve on the Prevalence of Vancomycin-Induced Nephrotoxicity in Combination With Tazobactam/Piperacillin or Cefepime: A Single-Institution Retrospective Study.

Clinical therapeutics

Okada N, Izumi Y, Nakamoto A, Chuma M, Goda M, Yagi K, Aizawa F, Hamano H, Zamami Y, Azuma M, Ishizawa K.
PMID: 34642081
Clin Ther. 2021 Nov;43(11):1910-1920.e3. doi: 10.1016/j.clinthera.2021.09.007. Epub 2021 Oct 09.

PURPOSE: Risk for vancomycin-induced nephrotoxicity (VIN) is reportedly reduced by AUC-guided vancomycin dosing. However, it remains unknown whether the increased VIN risk in combination treatment with vancomycin and tazobactam/piperacillin, which is a VIN risk factor, can be diminished by...

Cite
Okada N, Izumi Y, Nakamoto A, et al. Impact of Area Under the Concentration-Time Curve on the Prevalence of Vancomycin-Induced Nephrotoxicity in Combination With Tazobactam/Piperacillin or Cefepime: A Single-Institution Retrospective Study. Clin Ther. 2021;43(11):1910-1920.e3doi: 10.1016/j.clinthera.2021.09.007.
Okada, N., Izumi, Y., Nakamoto, A., Chuma, M., Goda, M., Yagi, K., Aizawa, F., Hamano, H., Zamami, Y., Azuma, M., & Ishizawa, K. (2021). Impact of Area Under the Concentration-Time Curve on the Prevalence of Vancomycin-Induced Nephrotoxicity in Combination With Tazobactam/Piperacillin or Cefepime: A Single-Institution Retrospective Study. Clinical therapeutics, 43(11), 1910-1920.e3. https://doi.org/10.1016/j.clinthera.2021.09.007
Okada, Naoto, et al. "Impact of Area Under the Concentration-Time Curve on the Prevalence of Vancomycin-Induced Nephrotoxicity in Combination With Tazobactam/Piperacillin or Cefepime: A Single-Institution Retrospective Study." Clinical therapeutics vol. 43,11 (2021): 1910-1920.e3. doi: https://doi.org/10.1016/j.clinthera.2021.09.007
Okada N, Izumi Y, Nakamoto A, Chuma M, Goda M, Yagi K, Aizawa F, Hamano H, Zamami Y, Azuma M, Ishizawa K. Impact of Area Under the Concentration-Time Curve on the Prevalence of Vancomycin-Induced Nephrotoxicity in Combination With Tazobactam/Piperacillin or Cefepime: A Single-Institution Retrospective Study. Clin Ther. 2021 Nov;43(11):1910-1920.e3. doi: 10.1016/j.clinthera.2021.09.007. Epub 2021 Oct 09. PMID: 34642081.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 231 entries